Drugs for Gastrointestinal Diseases Practice Questions

Q: Octreotide is not indicated in which of the following conditions?

Glucagonoma syndrome. **Explanation:** The correct answer is **D. Glucagonoma syndrome**. While Octreotide is a synthetic analog of somatostatin used to manage various neuroendocrine tumors, it is **not** the primary treatment for Glucagonoma syndrome in the context of this question's typical NEET-PG framing. In Glucagonoma, while Octreotide can reduce glucagon levels, it often fails to resolve the characteristic skin rash (**Necrolytic Migratory Erythema**) and can paradoxically worsen glucose intolerance by inhibiting insulin secretion. **Analysis of Options:** * **A. Variceal Bleeding:** Octreotide is a first-line treatment. It causes splanchnic vasoconstriction (by inhibiting glucagon, a vasodilator), thereby reducing portal venous pressure and controlling bleeding. * **B. Refractory Diarrhea in AIDS:** Octreotide is indicated for severe secretory diarrhea associated with AIDS or chemotherapy when standard antidiarrheals fail. It slows intestinal motility and reduces fluid secretion. * **C. Carcinoid Syndrome:** This is a classic indication. Octreotide effectively controls the flushing and severe diarrhea by inhibiting the release of serotonin and other vasoactive peptides. **NEET-PG High-Yield Pearls:** * **Mechanism:** Octreotide is a long-acting somatostatin analog (potent inhibitor of GH, glucagon, insulin, and gastrin). * **Side Effects:** The most common side effects are **steatorrhea** (due to inhibition of pancreatic enzymes) and **biliary sludge/gallstones** (due to inhibition of cholecystokinin and gallbladder contractility). * **Other Indications:** Acromegaly, VIPoma (Verner-Morrison syndrome), and Zollinger-Ellison syndrome. * **Clinical Note:** For Glucagonoma, the definitive treatment is surgical resection; Octreotide is only supportive.

Q: What is the most common side effect of the 5-HT3 antagonist drug alosetron?

Constipation. **Explanation:** **Alosetron** is a potent and selective **5-HT3 receptor antagonist** specifically used for the treatment of severe, diarrhea-predominant Irritable Bowel Syndrome (IBS-D) in women. **1. Why Constipation is the correct answer:** 5-HT3 receptors in the gastrointestinal tract play a crucial role in regulating visceral sensation and intestinal motility. By blocking these receptors, alosetron slows colonic transit time and increases water absorption. Consequently, **constipation** is the most frequent side effect, occurring in approximately 25-30% of patients. A more severe and life-threatening complication associated with alosetron is **ischemic colitis**, which led to its temporary withdrawal from the market (it is now available under a restricted prescribing program). **2. Why the other options are incorrect:** * **Pulmonary fibrosis:** This is a classic side effect of drugs like busulfan, bleomycin, and amiodarone, but it is not associated with 5-HT3 antagonists. * **Cardiac arrhythmias:** While other 5-HT3 antagonists used for emesis (like **Ondansetron**) are known to cause **QT interval prolongation**, this is not the primary or most common concern for alosetron. * **Headache:** Although headache is the most common side effect of *anti-emetic* 5-HT3 antagonists (e.g., Ondansetron), in the specific context of alosetron and IBS-D, constipation is significantly more prevalent and clinically relevant. **NEET-PG High-Yield Pearls:** * **Indication:** Only for **women** with severe **IBS-D** who haven't responded to conventional therapy. * **Black Box Warning:** Risk of severe constipation and **ischemic colitis**. * **Mechanism:** Reduces GI motility and decreases "visceral hypersensitivity" (pain). * **Comparison:** For IBS-Constipation (IBS-C), the 5-HT4 agonist **Tegaserod** or the chloride channel activator **Lubiprostone** are used.

Q: The inhibition of hydrochloric acid (HCl) secretion by omeprazole occurs within an hour, reaches a peak at 2 hours, and plateaus by the 4th day. After how many days will the secretion gradually normalize?

3-5 days. ### Explanation **Correct Answer: C. 3-5 days** **Mechanism of Action:** Omeprazole is a **Proton Pump Inhibitor (PPI)** that acts by irreversibly binding to the $H^+/K^+$-ATPase enzyme (the "proton pump") in the gastric parietal cells via covalent disulfide bonds. Because the inhibition is **irreversible**, the recovery of acid secretion does not depend on the drug's plasma half-life (which is short, ~1 hour), but rather on the **synthesis of new proton pumps**. It takes approximately **3 to 5 days** for the body to regenerate enough new $H^+/K^+$-ATPase molecules to restore gastric acid secretion to its baseline level. **Analysis of Incorrect Options:** * **Option A ( 5 days):** While some residual effect may linger, the clinically significant normalization of acid secretion typically occurs within the 3-5 day window as the turnover of parietal cell proteins is relatively rapid. **NEET-PG High-Yield Pearls:** * **Prodrug Status:** PPIs are inactive at neutral pH; they are basic compounds that require an **acidic environment** (within the canaliculi of parietal cells) to be converted into the active **sulfenamide** form. * **Administration Timing:** PPIs should be taken **30–60 minutes before a meal** (usually breakfast) because the number of $H^+/K^+$-ATPase pumps at the canalicular surface is maximal after a period of fasting. * **Steady State:** It takes 3-4 days of continuous dosing to reach a "plateau" or steady-state inhibition (approx. 70% of pumps), which correlates with the time it takes for the recovery of secretion.

Q: Certolizumab is used in the treatment of:

Crohn's disease. **Explanation:** **Certolizumab pegol** is a recombinant, humanized antibody fragment (Fab') conjugated to polyethylene glycol (PEG). It acts as a potent **TNF-α (Tumor Necrosis Factor-alpha) inhibitor**. 1. **Why Crohn’s Disease is Correct:** TNF-α is a key pro-inflammatory cytokine involved in the pathogenesis of Inflammatory Bowel Disease (IBD). Certolizumab neutralizes both membrane-bound and soluble TNF-α, reducing intestinal inflammation. It is specifically FDA-approved for reducing signs and symptoms and maintaining clinical response in adult patients with moderately to severely active **Crohn's disease** who have had an inadequate response to conventional therapy. 2. **Why Other Options are Incorrect:** * **Multiple Sclerosis (MS):** TNF-α inhibitors are generally **contraindicated** in MS as they can exacerbate demyelinating diseases. MS is typically treated with Interferon-beta, Glatiramer acetate, or Natalizumab. * **Colorectal Carcinoma:** This is treated with chemotherapy and targeted therapies like Bevacizumab (anti-VEGF) or Cetuximab (anti-EGFR), not TNF inhibitors. * **SLF2:** This is not a recognized clinical entity relevant to TNF-inhibitor therapy (likely a distractor). **NEET-PG High-Yield Pearls:** * **Unique Structure:** Unlike Infliximab or Adalimumab, Certolizumab **lacks an Fc portion**. This prevents complement activation or antibody-dependent cellular cytotoxicity (ADCC). * **Pregnancy:** Because it lacks the Fc region, it does not undergo active placental transfer, making it a preferred TNF inhibitor during **pregnancy**. * **Pegylation:** The addition of PEG increases the half-life, allowing for subcutaneous dosing every 2–4 weeks. * **Other Indications:** Rheumatoid arthritis, Psoriatic arthritis, and Ankylosing spondylitis.

Q: What is the primary role of antacids in the management of peptic ulcer disease?

Ulcer healing. **Explanation:** The primary therapeutic goal of antacids in peptic ulcer disease (PUD) is to facilitate **ulcer healing**. While antacids are weak bases that neutralize gastric hydrochloric acid (HCl), their role extends beyond simple pH adjustment. By raising the gastric pH above 3.5–4.0, antacids inhibit the conversion of pepsinogen to **pepsin** (a proteolytic enzyme that degrades the mucosal barrier) and reduce the direct corrosive action of acid on the ulcer crater. This creates a favorable environment for mucosal regeneration and healing. **Analysis of Options:** * **A. Pain relief:** While antacids do provide rapid, symptomatic relief from "heartburn" or burning epigastric pain, this is considered a **secondary benefit** or a palliative effect rather than the primary clinical objective in treating the underlying pathology of PUD. * **C. Helicobacter pylori eradication:** Antacids have no antimicrobial properties. Eradication requires a combination of antibiotics (e.g., Clarithromycin, Amoxicillin) and Proton Pump Inhibitors (PPIs). * **D. All of the above:** Incorrect, as antacids do not affect *H. pylori*. **High-Yield NEET-PG Pearls:** * **Potency:** Measured in **mEq of Acid Neutralizing Capacity (ANC)**. It is defined as the number of mEq of 1N HCl brought to pH 3.5 in 15 minutes. * **Systemic vs. Non-systemic:** Sodium bicarbonate is systemic (can cause metabolic alkalosis); Magnesium and Aluminum salts are non-systemic. * **Side Effects:** Remember the mnemonic **"M-D, A-C"**: **M**agnesium causes **D**iarrhea, **A**luminum causes **C**onstipation. * **Drug Interactions:** Antacids can decrease the absorption of Tetracyclines, Iron salts, and Fluoroquinolones due to chelation.

Q: Which of the following drugs is used in the management of drug-induced ulcers?

Omeprazole. **Explanation:** The management of drug-induced ulcers, particularly those caused by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), focuses on potent acid suppression to allow the gastric mucosa to heal. **Why Omeprazole is the Correct Answer:** Proton Pump Inhibitors (PPIs) like **Omeprazole** are considered the **drugs of choice** for both the treatment and prevention of NSAID-induced gastric and duodenal ulcers. They work by irreversibly inhibiting the $H^+/K^+$-ATPase pump in gastric parietal cells. Clinical trials have consistently shown that PPIs are superior to $H_2$ blockers and Misoprostol in terms of healing rates and patient tolerance. **Analysis of Incorrect Options:** * **Antacids (A):** These provide symptomatic relief by neutralizing existing gastric acid but do not promote significant ulcer healing or provide long-term protection. * **Ranitidine (B):** While $H_2$ receptor antagonists can heal NSAID-induced duodenal ulcers, they are significantly **less effective** than PPIs for healing gastric ulcers (the more common site for NSAID injury). * **Misoprostol (D):** This is a $PGE_1$ analogue that replaces the prostaglandins depleted by NSAIDs. While it is highly effective for **prevention**, it is less effective than PPIs for **healing** active ulcers and is poorly tolerated due to side effects like abdominal cramps and diarrhea. **NEET-PG High-Yield Pearls:** * **Drug of Choice for NSAID-induced ulcers:** PPIs (e.g., Omeprazole). * **Specific Prostaglandin Analogue for Prevention:** Misoprostol (specifically indicated for preventing NSAID-induced ulcers in high-risk patients). * **Most common site for NSAID ulcers:** Stomach (Gastric ulcer). * **Most common site for H. pylori ulcers:** Duodenum.

Q: Which of the following is the drug of choice for the treatment of peptic ulcer disease?

Omeprazole. **Explanation:** **Correct Option: A. Omeprazole** Proton Pump Inhibitors (PPIs) like Omeprazole are the **drug of choice (DOC)** for Peptic Ulcer Disease (PUD), including gastric and duodenal ulcers [1], [2]. They act by irreversibly inhibiting the **H+/K+ ATPase pump** (the final common pathway of acid secretion) in the gastric parietal cells [1]. PPIs are superior to other agents because they provide the most potent and prolonged inhibition of both basal and stimulated gastric acid secretion [2], achieving healing rates of >90% within 4–8 weeks. **Incorrect Options:** * **B. Pirenzepine:** This is a selective M1 muscarinic antagonist. While it reduces acid secretion, it is significantly less effective than PPIs and H2 blockers and is rarely used clinically due to anticholinergic side effects. * **C. Ranitidine:** An H2 receptor antagonist [1]. While previously a mainstay for PUD, it is less potent than PPIs because it only blocks the histamine pathway, leaving the gastrin and acetylcholine pathways active [2]. It also carries a risk of tachyphylaxis (tolerance). * **D. Sucralfate:** A cytoprotective agent that forms a physical barrier over the ulcer base. It is used as an adjuvant therapy but is not the primary drug of choice as it does not affect the underlying acid secretion. **High-Yield Clinical Pearls for NEET-PG:** * **Administration:** PPIs are prodrugs and should be taken **30–60 minutes before breakfast** for maximal efficacy (when the number of H+/K+ ATPase pumps is highest). * **H. pylori Eradication:** PPIs are a mandatory component of the "Triple Therapy" (PPI + Clarithromycin + Amoxicillin/Metronidazole) [1], [2]. * **Zollinger-Ellison Syndrome:** PPIs are also the drug of choice for this hypersecretory condition [1], [2]. * **Side Effects:** Long-term PPI use is associated with Vitamin B12 deficiency, hypomagnesemia, and an increased risk of *C. difficile* infections and osteoporotic fractures [2].

Q: Which prostaglandin is useful for the prevention of duodenal ulcer?

Misoprostol. **Explanation:** **Misoprostol** is a synthetic **Prostaglandin E1 (PGE1) analogue**. It is the correct answer because prostaglandins (specifically PGE1 and PGI2) play a vital role in gastric mucosal protection. Misoprostol acts on EP3 receptors on parietal cells to inhibit gastric acid secretion and stimulates mucus and bicarbonate secretion (cytoprotective effect). It is specifically FDA-approved for the **prevention of NSAID-induced gastric and duodenal ulcers**, as NSAIDs inhibit the cyclooxygenase (COX) enzyme, leading to a deficiency of endogenous protective prostaglandins. **Analysis of Incorrect Options:** * **Dinoprost (PGF2α):** Primarily used in obstetrics for induction of labor or mid-trimester abortion due to its potent uterine-contracting properties. * **Alprostadil (PGE1):** While also a PGE1 analogue, it is used clinically for maintaining the patency of the **ductus arteriosus** in neonates with congenital heart defects and for treating erectile dysfunction (intracavernosal injection). * **Carboprost (15-methyl PGF2α):** Used to control **Postpartum Hemorrhage (PPH)** by causing uterine contraction when oxytocin fails. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Misoprostol is the specific DOC for preventing ulcers in patients on long-term NSAID therapy, though Proton Pump Inhibitors (PPIs) are more commonly used in practice due to better tolerability. * **Side Effects:** The most common side effect is **diarrhea** and abdominal cramps. * **Contraindication:** It is strictly **contraindicated in pregnancy** (Category X) because it is an abortifacient (causes uterine contractions). It is often used in combination with Mifepristone for medical termination of pregnancy (MTP).

Q: Which laxative is used in the management of hepatic encephalopathy?

Lactulose. ### Explanation **Correct Option: A (Lactulose)** Lactulose is a non-absorbable disaccharide that serves as the mainstay of treatment for hepatic encephalopathy (HE) due to its unique dual mechanism: 1. **Ammonia Trapping:** Colonic bacteria ferment lactulose into lactic and acetic acids. This acidifies the gut lumen (lowers pH), converting diffusible ammonia ($NH_3$) into non-diffusible ammonium ions ($NH_4^+$), which are then excreted in the stool. 2. **Osmotic Laxation:** As an osmotic laxative, it increases fecal bulk and speeds up transit time, reducing the duration available for ammonia production and absorption by gut flora. **Incorrect Options:** * **B (Sodium picosulfate):** A stimulant laxative often used for bowel preparation before colonoscopy. It has no effect on ammonia metabolism. * **C (Lubiprostone):** A chloride channel activator (ClC-2) used for chronic idiopathic constipation and IBS-C. It does not lower systemic ammonia levels. * **D (Bisacodyl):** A diphenylmethane derivative stimulant laxative. While effective for acute constipation, it lacks the acidifying properties required to treat HE. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Goal:** In HE, lactulose dosage is titrated to achieve **2–3 soft stools per day**. * **Rifaximin:** Often added to lactulose for secondary prevention of HE; it is a non-absorbable antibiotic that kills ammonia-producing bacteria. * **Other uses of Lactulose:** It is also used to treat chronic constipation and can help prevent portal-systemic encephalopathy. * **Side Effects:** Flatulence, abdominal cramps, and electrolyte imbalance (due to diarrhea).

Q: To prevent motion sickness, when should an antiemetic drug be administered?

One hour before the journey. **Explanation:** 1. Why Option C is Correct:Motion sickness is caused by a sensory mismatch between the vestibular system and visual inputs. Antiemetics used for this condition (primarily **Antimuscarinics** like Hyoscine/Scopolamine or **H1 Antihistaminics** like Promethazine and Cyclizine) work by blocking the vestibular nuclei and the vomiting center [1, 2]. These drugs are **prophylactic**, not curative. For oral medications, it takes approximately 30 to 60 minutes to reach therapeutic plasma concentrations. Therefore, administering the drug **one hour before the journey** ensures the vestibular system is suppressed before the provocative stimulus begins. 2. Why Other Options are Incorrect:* **Option A & D:** Administering the drug 12 to 24 hours prior is ineffective because the drug’s peak effect will have passed, and plasma levels will likely be sub-therapeutic by the time the journey starts.* **Option B:** Once the vomiting reflex is triggered and the "chemoreceptor trigger zone" (CTZ) is activated, oral drugs are poorly absorbed due to gastric stasis and are often vomited out before they can act. Antiemetics are significantly less effective if given after symptoms have already commenced. 3. NEET-PG High-Yield Pearls:* **Drug of Choice:** **Hyoscine (Scopolamine)** is the most effective drug for motion sickness [1].* **Route of Choice:** For long journeys, the **Transdermal patch** of Hyoscine is preferred (applied behind the ear 4 hours before the journey) [1].* **Mechanism:** These drugs act on **M1 receptors** in the vestibular apparatus and **H1 receptors** in the nucleus tractus solitarius [1, 2].* **Note:** Selective 5-HT3 antagonists (like Ondansetron) are **ineffective** in motion sickness.

Question 1

Octreotide is not indicated in which of the following conditions?

Accepted Answer

Glucagonoma syndrome

Answer

Variceal bleeding

Answer

Refractory diarrhea in AIDS

Answer

Carcinoid syndrome

Question 2

What is the most common side effect of the 5-HT3 antagonist drug alosetron?

Accepted Answer

Constipation

Answer

Pulmonary fibrosis

Answer

Cardiac arrhythmias

Answer

Headache

Question 3

The inhibition of hydrochloric acid (HCl) secretion by omeprazole occurs within an hour, reaches a peak at 2 hours, and plateaus by the 4th day. After how many days will the secretion gradually normalize?

Accepted Answer

3-5 days

Answer

Less than 24 hours

Answer

1-2 days

Answer

More than 5 days

Question 4

Certolizumab is used in the treatment of:

Accepted Answer

Crohn's disease

Answer

Multiple Sclerosis

Answer

Colorectal Carcinoma

Answer

SLF2

Question 5

What is the primary role of antacids in the management of peptic ulcer disease?

Accepted Answer

Ulcer healing

Answer

Pain relief

Answer

Helicobacter pylori eradication

Answer

All of the above

Question 6

Which of the following drugs is used in the management of drug-induced ulcers?

Accepted Answer

Omeprazole

Answer

Antacids

Answer

Ranitidine

Answer

Misoprostol

Question 7

Which of the following is the drug of choice for the treatment of peptic ulcer disease?

Accepted Answer

Omeprazole

Answer

Pirenzepine

Answer

Ranitidine

Answer

Sucralfate

Question 8

Which prostaglandin is useful for the prevention of duodenal ulcer?

Accepted Answer

Misoprostol

Answer

Dinoprost

Answer

Alprostadil

Answer

Carboprost

Question 9

Which laxative is used in the management of hepatic encephalopathy?

Accepted Answer

Lactulose

Answer

Sodium picosulfate

Answer

Lubiprostone

Answer

Bisacodyl

Question 10

To prevent motion sickness, when should an antiemetic drug be administered?

Accepted Answer

One hour before the journey

Answer

A day before the journey

Answer

After the first episode of vomiting

Answer

Twelve hours before the journey

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?